Positron Emission Tomography Imaging of [11C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A. Issue 5 (22nd July 2019)
- Record Type:
- Journal Article
- Title:
- Positron Emission Tomography Imaging of [11C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A. Issue 5 (22nd July 2019)
- Main Title:
- Positron Emission Tomography Imaging of [11C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A
- Authors:
- Billington, Sarah
Shoner, Steven
Lee, Scott
Clark‐Snustad, Kindra
Pennington, Matthew
Lewis, David
Muzi, Mark
Rene, Shirley
Lee, Jean
Nguyen, Tot Bui
Kumar, Vineet
Ishida, Kazuya
Chen, Laigao
Chu, Xiaoyan
Lai, Yurong
Salphati, Laurent
Hop, Cornelis E.C.A.
Xiao, Guangqing
Liao, Mingxiang
Unadkat, Jashvant D. - Abstract:
- Abstract : Using positron emission tomography imaging, we determined the hepatic concentrations and hepatobiliary transport of [ 11 C]rosuvastatin (RSV; i.v. injection) in the absence ( n = 6) and presence ( n = 4 of 6) of cyclosporin A (CsA; i.v. infusion) following a therapeutic dose of unlabeled RSV (5 mg, p.o.) in healthy human volunteers. The sinusoidal uptake, sinusoidal efflux, and biliary efflux clearance (CL; mL/minute) of [ 11 C]RSV, estimated through compartment modeling were 1, 205.6 ± 384.8, 16.2 ± 11.2, and 5.1 ± 1.8, respectively ( n = 6). CsA (blood concentration: 2.77 ± 0.24 μM), an organic‐anion‐transporting polypeptide, Na + ‐taurocholate cotransporting polypeptide, and breast cancer resistance protein inhibitor increased [ 11 C]RSV systemic blood exposure (45%; P < 0.05), reduced its biliary efflux CL (52%; P < 0.05) and hepatic uptake (25%; P > 0.05) but did not affect its distribution into the kidneys. CsA increased plasma concentrations of coproporphyrin I and III and total bilirubin by 297 ± 69%, 384 ± 102%, and 81 ± 39%, respectively ( P < 0.05). These data can be used in the future to verify predictions of hepatic concentrations and hepatobiliary transport of RSV.
- Is Part Of:
- Clinical pharmacology & therapeutics. Volume 106:Issue 5(2019)
- Journal:
- Clinical pharmacology & therapeutics
- Issue:
- Volume 106:Issue 5(2019)
- Issue Display:
- Volume 106, Issue 5 (2019)
- Year:
- 2019
- Volume:
- 106
- Issue:
- 5
- Issue Sort Value:
- 2019-0106-0005-0000
- Page Start:
- 1056
- Page End:
- 1066
- Publication Date:
- 2019-07-22
- Subjects:
- Pharmacology -- Periodicals
Therapeutics -- Periodicals
615.5 - Journal URLs:
- http://www.nature.com/clpt/index.html ↗
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1532-6535 ↗
http://www.nature.com/ ↗
http://firstsearch.oclc.org ↗
http://www.mosby.com/cpt ↗
http://www.sciencedirect.com/science/journal/00099236 ↗
http://www2.us.elsevierhealth.com/scripts/om.dll/serve?action=searchDB&searchdbfor=home&id=cp ↗ - DOI:
- 10.1002/cpt.1506 ↗
- Languages:
- English
- ISSNs:
- 0009-9236
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.330000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 11842.xml